Mizuho Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Stock analysts at Mizuho initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report issued on Wednesday, Marketbeat reports. The firm set an “outperform” rating and a $205.00 price target on the stock. Mizuho’s price target would indicate a potential upside of 110.52% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Chardan Capital raised their target price on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Craig Hallum assumed coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They issued a “buy” rating and a $175.00 price objective on the stock. Canaccord Genuity Group raised their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. BTIG Research boosted their target price on Palvella Therapeutics from $167.00 to $192.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Trading Down 3.6%

NASDAQ:PVLA opened at $97.38 on Wednesday. The stock has a market capitalization of $1.15 billion, a PE ratio of -37.03 and a beta of -0.16. Palvella Therapeutics has a 1-year low of $12.02 and a 1-year high of $114.69. The firm has a fifty day simple moving average of $93.23 and a 200 day simple moving average of $64.66.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PVLA. Suvretta Capital Management LLC boosted its holdings in Palvella Therapeutics by 15.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock valued at $51,556,000 after purchasing an additional 107,937 shares during the period. Frazier Life Sciences Management L.P. boosted its stake in Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after buying an additional 32,388 shares during the period. First Light Asset Management LLC purchased a new position in Palvella Therapeutics during the third quarter worth about $33,949,000. Vanguard Group Inc. increased its stake in Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after acquiring an additional 330,847 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in Palvella Therapeutics in the 3rd quarter worth about $21,255,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.